NCT01495468View on ClinicalTrials.gov

Phase III Clinical Study of Pegylated Somatropin (PEG Somatropin) to Treat Growth Hormone Deficiency Children

PHASE3CompletedINTERVENTIONAL
Enrollment

343

Participants

Timeline

Start Date

March 31, 2007

Primary Completion Date

January 31, 2008

Study Completion Date

March 31, 2008

Conditions
Growth Hormone Deficiency
Interventions
BIOLOGICAL

PEG-somatropin

drug:pegylated somatropin 0.2mg/(kg.w), once per week for 6 months drug: Jintropin AQ, 0.25mg/(kg.w), once per day for 6 months

Trial Locations (6)

Unknown

Beijing

Changchun

Guangzhou

Hangzhou

Shanghai

Wuhan

All Listed Sponsors
collaborator

Tongji Hospital

OTHER

collaborator

First Affiliated Hospital, Sun Yat-Sen University

OTHER

collaborator

Capital Medical University

OTHER

collaborator

Children's Hospital of Fudan University

OTHER

collaborator

The First Hospital of Jilin University

OTHER

lead

Changchun GeneScience Pharmaceutical Co., Ltd.

INDUSTRY

NCT01495468 - Phase III Clinical Study of Pegylated Somatropin (PEG Somatropin) to Treat Growth Hormone Deficiency Children | Biotech Hunter | Biotech Hunter